COMMUNIQUÉS West-GlobeNewswire

AAPS Calls for Elimination of ‘Diversity, Equity, and Inclusion’ Ideology from Medicine
17/06/2024
TUCSON, Ariz., June 17, 2024 (GLOBE NEWSWIRE) -- In a statement adopted on June 17, the Association of American Physicians and Surgeons calls for “urgent actions … to eliminate the destructive ‘diversity, equity, and [...]
The era of biosolutions. Outlook upgraded for 2024
17/06/2024
Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to 35-36%. Novonesis’ [...]
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
17/06/2024
June 17, 2024 Announcement no. 13 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER [...]
EchoNous Announces Sale of 157 Units of Kosmos Ultrasound Technology to Madrid’s Primary Care System
17/06/2024
MADRID, June 17, 2024 (GLOBE NEWSWIRE) -- EchoNous, a leader in AI-enabled point-of-care ultrasound systems (POCUS), is excited to announce the installation of 157 Kosmos units in more than 150 primary care centers [...]
TALVEY®▼ (talquetamab) a permis d’obtenir des réponses très durables et à plus long terme chez des patients atteints de myélome multiple récidivant ou réfractaire
17/06/2024
Taux de survie globale à 24 mois de 67 pour cent obtenu avec le talquetamab administré à raison de 0,8 mg/kg toutes les deux semaines dans l’étude de la Phase 1/2 MonumenTAL-11 1 BEERSE, BELGIQUE, 17 juin 2024 (GLOBE [...]
Les résultats issus de l’étude RESONATE-2 de référence confirment le bénéfice durable en matière de survie d’IMBRUVICA® (ibrutinib) dans le traitement de première intention de la leucémie lymphoïde chronique avec une durée de suivi allant jusqu’à 10 ans
17/06/2024
Les données issues de RESONATE-2 présentées au congrès 2024 de l’European Hematology Association (EHA) fournissent des résultats et des données de sécurité à plus long terme que ceux jamais rapportés pour un inhibiteur [...]
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
17/06/2024
First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older Represents first BLA for a [...]
EchoNous Announces Sale of 157 Units of Kosmos Ultrasound Technology to Madrid’s Primary Care System
17/06/2024
MADRID, Spain, June 17, 2024 (GLOBE NEWSWIRE) -- EchoNous, a leader in AI-enabled point-of-care ultrasound systems (POCUS), is excited to announce the installation of 157 Kosmos units in more than 150 primary care [...]
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
17/06/2024
HOUSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar [...]
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
17/06/2024
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today [...]
Transactions in Connection with Share Buy-back Program
17/06/2024
Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
17/06/2024
– The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications – – No Safety or Futility Concerns Were Raised Based on the Efficacy and Safety Assessment of [...]
Philips Zenition 90 Motorized receives FDA 510(k) clearance, helping clinicians deliver high quality care with a high-powered and fast motorized mobile C-arm
17/06/2024
June 17, 2024 Intuitive motorization for greater control and high-power (25 kW [1]) for state-of-the-art image quality supports complex vascular needs and a full range of clinical procedures Automated workflows [...]
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
17/06/2024
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
17/06/2024
MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Bicycle Health and OpiAID research the impact of wearable technology on virtual opioid use disorder treatment
17/06/2024
The companies seek to learn if biometrics and data science can help personalize treatment plans, identify withdrawal symptoms and help patients find long-term recovery BOSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Bicycle [...]
Shineco Enters into an Agreement with Turing Video to Jointly Develop Intelligent Health Care Products
17/06/2024
Beijing, June 17, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 14, 2024 [...]
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
16/06/2024
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the [...]
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
16/06/2024
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time [...]

Pages